Latest papers

Lipid-soluble cardiodepressant factor vs. water-soluble myocardial depressant factor-like substances in shock.

Increase of cardiodepressant activity in medium incubating the posterior pituitary lobe in situ during vagal nerve stimulation in rat.

Beneficial effects of transforming growth factor-beta and tissue plasminogen activator in splanchnic artery occlusion and reperfusion in cats.

Cardiovascular dysfunction in septic shock.

Protection of endothelial damage and systemic shock by benidipine, a calcium antagonist, in rats subjected to splanchnic ischemia and reperfusion.

Protective effect of cloricromene, a coumarine derivative, in hypovolemic hemorrhagic shock in the rat.

hemofiltration reverses left ventricular dysfunction during sepsis in dogs.

Protective effects of KW-3635, a novel thromboxane A2 antagonist, in murine traumatic shock.

A circulating myocardial depressant substance in septic shock.

Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock.

Protective effects of the specific thromboxane receptor antagonist (+)-S145Na in splanchnic artery occlusion shock in rats.

Protective effects of a novel 21-aminosteroid during splanchnic artery occlusion shock.

Effects of fructose 1,6-diphosphate on splanchnic artery occlusion shock in the rat.

Pharmacological modulation of myocardial depressant factor as a mediator of circulatory shock.

Beneficial effects of a specific leukotriene receptor antagonist in splanchnic artery occlusion shock.

Myocardial dysfunction in sepsis. Recent insights.

A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock.

Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.

Current concepts on myocardial depressant factor.

Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock.